Publication date: Jun 18, 2024
Phase 2 trial shows dalzanemdor’s safety, disease’s cognitive impact. SURVEYOR study finds significant differences between patients, healthy adults.
| Concepts | Keywords |
|---|---|
| Adults | Affects |
| Clinical | Cognition |
| Disease | Cognitive |
| Healthy | Dalzanemdor |
| Huntington | Disease |
| Finds | |
| Huntington | |
| Impact | |
| Phase | |
| Safe | |
| Safety | |
| Shows | |
| Surveyor | |
| Trial |
(Visited 1 times, 1 visits today)